AVITA Medical, Inc. (AVHHL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 30M 60M 90M Q2 '19: 5.5M Q3 '19: 8.5M Q4 '19: 10.7M Q1 '20: 12.8M Q2 '20: 14.3M Q3 '20: 16.1M Q4 '20: 17.9M Q1 '21: 22.8M Q2 '21: 29.2M Q3 '21: 31.2M Q4 '21: 33M Q1 '22: 31.8M Q2 '22: 29.8M Q3 '22: 31.9M Q4 '22: 34.4M Q1 '23: 37.4M Q2 '23: 40.9M Q3 '23: 45.4M Q4 '23: 50.1M Q1 '24: 50.7M Q2 '24: 54.1M Q3 '24: 59.9M Q4 '24: 63.9M Q1 '25: 71.1M Q2 '25: 74.2M Q3 '25: 71.7M Q4 '25: 70.9M Q1 '26: 71.6M Q2 '26: 74.9M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Gross Profit TTM

0 25M 50M 75M Q2 '19: 4.2M Q3 '19: 6.8M Q4 '19: 8.4M Q1 '20: 10.2M Q2 '20: 11.3M Q3 '20: 12.8M Q4 '20: 14.7M Q1 '21: 18M Q2 '21: 23.3M Q3 '21: 25.1M Q4 '21: 26.9M Q1 '22: 26.1M Q2 '22: 24.8M Q3 '22: 26.4M Q4 '22: 28.4M Q1 '23: 31.5M Q2 '23: 34.1M Q3 '23: 38.1M Q4 '23: 42.4M Q1 '24: 43.1M Q2 '24: 46.6M Q3 '24: 51.4M Q4 '24: 55.2M Q1 '25: 61.2M Q2 '25: 63.1M Q3 '25: 60.6M Q4 '25: 58.8M Q1 '26: 58.9M Q2 '26: 61.7M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Income TTM

-75M -50M -25M 0 25M 50M 75M Q2 '19: -25.5M Q3 '19: -24.1M Q4 '19: -28.4M Q1 '20: -37.1M Q2 '20: -42.7M Q3 '20: -49.2M Q4 '20: -44.3M Q1 '21: -34.9M Q2 '21: -26.5M Q3 '21: -22.3M Q4 '21: -25.1M Q1 '22: -28.6M Q2 '22: -30.3M Q3 '22: -30.1M Q4 '22: -27.5M Q1 '23: -27.9M Q2 '23: -32.7M Q3 '23: -36.3M Q4 '23: -42.7M Q1 '24: -50M Q2 '24: -54.4M Q3 '24: -58.9M Q4 '24: -56.6M Q1 '25: -51.2M Q2 '25: -46.7M Q3 '25: -42.1M Q4 '25: -42.5M Q1 '26: -39.5M Q2 '26: -35.2M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income TTM

-75M -50M -25M 0 25M 50M 75M Q2 '19: -25.1M Q3 '19: -23.6M Q4 '19: -27.9M Q1 '20: -36.7M Q2 '20: -42M Q3 '20: -48.7M Q4 '20: -43.8M Q1 '21: -34.8M Q2 '21: -26.6M Q3 '21: -22.3M Q4 '21: -25.1M Q1 '22: -28.6M Q2 '22: -30.2M Q3 '22: -29.8M Q4 '22: -26.7M Q1 '23: -26.4M Q2 '23: -30.5M Q3 '23: -33.7M Q4 '23: -35.4M Q1 '24: -44.8M Q2 '24: -49.8M Q3 '24: -57.3M Q4 '24: -61.8M Q1 '25: -57M Q2 '25: -51.6M Q3 '25: -48.6M Q4 '25: -48.6M Q1 '26: -45.3M Q2 '26: -43.1M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue TTM

0 5M 10M 15M Q2 '19: 1.3M Q3 '19: 1.7M Q4 '19: 2.3M Q1 '20: 2.6M Q2 '20: 3M Q3 '20: 3.3M Q4 '20: 3.3M Q1 '21: 4.8M Q2 '21: 5.9M Q3 '21: 6.1M Q4 '21: 6.1M Q1 '22: 5.7M Q2 '22: 5.1M Q3 '22: 5.5M Q4 '22: 6M Q1 '23: 5.9M Q2 '23: 6.7M Q3 '23: 7.3M Q4 '23: 7.8M Q1 '24: 7.6M Q2 '24: 7.5M Q3 '24: 8.6M Q4 '24: 9.1M Q1 '25: 10.4M Q2 '25: 11.8M Q3 '25: 11.8M Q4 '25: 12.8M Q1 '26: 13.5M Q2 '26: 13.9M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Cash Flow TTM

-60M -40M -20M 0 20M 40M 60M Q2 '20: -22.7M Q3 '20: -25.6M Q4 '20: -26.6M Q1 '21: -27.8M Q2 '21: -25.9M Q3 '21: -18.8M Q4 '21: -18M Q1 '22: -18.9M Q2 '22: -18.4M Q3 '22: -20.6M Q4 '22: -19.1M Q1 '23: -18.8M Q2 '23: -24.4M Q3 '23: -30.6M Q4 '23: -38M Q1 '24: -49.8M Q2 '24: -53.5M Q3 '24: -51.7M Q4 '24: -48.9M Q1 '25: -38.4M Q2 '25: -35.8M Q3 '25: -33.8M Q4 '25: -31.2M Q1 '26: -31M Q2 '26: -24.2M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q2 '20: -23.3M Q3 '20: -26.3M Q4 '20: -27.5M Q1 '21: -28.8M Q2 '21: -26.8M Q3 '21: -19.5M Q4 '21: -18.5M Q1 '22: -19.1M Q2 '22: -18.7M Q3 '22: -21M Q4 '22: -19.5M Q1 '23: -19.5M Q2 '23: -25.1M Q3 '23: -31.7M Q4 '23: -39.4M Q1 '24: -52M Q2 '24: -58.1M Q3 '24: -59.6M Q4 '24: -58.1M Q1 '25: -46.6M Q2 '25: -42M Q3 '25: -37.1M Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q3 '18: 13.2M Q4 '18: 14.2M Q1 '19: 18.3M Q2 '19: 18.7M Q3 '19: 18.7M Q4 '19: 19.9M Q1 '20: 21.2M Q2 '20: 21.4M Q3 '20: 21.5M Q4 '20: 21.6M Q1 '21: 22.7M Q2 '21: 24.9M Q3 '21: 24.9M Q1 '22: 24.9M Q2 '22: 25M Q3 '22: 25M Q1 '23: 25.2M Q2 '23: 25.2M Q3 '23: 25.4M Q1 '24: 25.6M Q2 '24: 25.8M Q3 '24: 26M Q1 '25: 26.3M Q2 '25: 26.4M Q3 '25: 28.4M Q1 '26: 30.5M Q2 '26: 30.7M Q1 '19 Q1 '20 Q1 '21 Q2 '22 Q3 '23 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.70 -1.80 -0.90 0.00 0.90 1.80 2.70 Q2 '19: -1.57 Q3 '19: -1.38 Q4 '19: -0.41 Q1 '20: 0.64 Q2 '20: 0.45 Q3 '20: 1.12 Q4 '20: 0.85 Q1 '21: 0.40 Q2 '21: 1.19 Q3 '21: 0.95 Q4 '21: 1.03 Q1 '22: 1.15 Q2 '22: 1.21 Q3 '22: 1.19 Q4 '22: 1.07 Q1 '23: 0.32 Q2 '23: -0.34 Q3 '23: -0.90 Q4 '23: -1.40 Q1 '24: -1.76 Q2 '24: -1.95 Q3 '24: -2.23 Q4 '24: -2.39 Q1 '25: -2.19 Q2 '25: -1.97 Q3 '25: -1.81 Q4 '25: -1.74 Q1 '26: -1.56 Q2 '26: -1.43 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.